z-logo
Premium
HIV positive men with Non‐Alcoholic Steatohepatitis (NASH) have altered hepatic fatty acid composition
Author(s) -
Arendt Bianca Maria,
Mohammed Saira S.,
Aghdassi Elaheh,
Salit Irving E.,
Guindi Maha,
Ma David W. L.,
Allard Johane P.
Publication year - 2008
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.22.2_supplement.717
Subject(s) - steatohepatitis , linoleic acid , medicine , eicosapentaenoic acid , arachidonic acid , docosahexaenoic acid , polyunsaturated fatty acid , steatosis , endocrinology , chemistry , fatty liver , fatty acid , biochemistry , disease , enzyme
Hepatic fatty acid (FA) composition might play a role in the development of simple hepatic steatosis (SS) to NASH. Aim was to compare hepatic FA composition in HIV+ men with NASH to those with SS. METHOD: Prospective, cross‐sectional study in 19 HIV+ men (6 SS, 13 NASH). Hepatic FA composition (% of total lipid, gas chromatography) and lipid peroxidation (LPO, testkit), blood biochemistry, anthropometry, medical history and dietary intake were assessed. Mann‐Whitney‐U test was used, p<0.05 is considered significant. RESULTS: HIV‐NASH had lower arachidonic acid (AA) (mean±SEM: 1.4±0.4 vs. 3.0±0.5%) and docosahexaenoic acid (DHA) (0.37±0.86 vs. 0.86±0.10%) compared to HIV‐SS. Metabolite/precursor ratio was significantly reduced for n‐6 PUFA (AA/linoleic acid: 0.24±0.04 vs. 0.45±0.12) and a trend was seen for n‐3 ((eicosapentaenoic acid +DHA)/linolenic acid: 1.4±0.3 vs. 3.0±0.7; p=0.062). HIV‐NASH were older (47±2 vs. 40±2 y), but LPO, body mass index, diet and other variables were not different. Similar results were found when HIV‐NASH were compared to healthy controls. In addition, n6/n3 ratio was increased (HIV‐NASH: 9.1±1.4 vs. controls: 5.4±0.5). CONCLUSION: HIV+ men with NASH have reduced long‐chain PUFA and metabolite/precursor ratios in hepatic total lipids, suggesting changes in FA metabolism. Other factors do not seem to play a role. Funded by Ontario HIV Treatment Network.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom